Clinical Trial Update: A Multi-center, Randomized, Blinded Evaluator, Active Control, Parallel, Phase III Study to Evaluate the Efficacy and Safety of TJO-002 in POAG or Ocular Hypertension Patients [Phase 3]

View source ↗

Summary

Phase III clinical trial evaluating TJO-002 for primary open-angle glaucoma and ocular hypertension has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• TJO-002

Snippet

Sponsor: Taejoon Pharmaceutical Co., Ltd. | Conditions: Primary Open-angle Glaucoma, Ocular Hypertension | Phase 3 | Status: COMPLETED